Cancer Cell
Volume 29, Issue 3, 14 March 2016, Pages 311-323
Journal home page for Cancer Cell

Article
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma

https://doi.org/10.1016/j.ccell.2016.02.011Get rights and content
Under an Elsevier user license
open archive

Highlights

  • High-throughput screening identifies inhibitors of MYC-driven MB

  • HDACIs inhibit growth of murine and human MYC-driven MB cells

  • HDACIs and PI3KIs cooperate to activate FOXO1 and suppress tumor growth in vitro

  • HDACIs and PI3KIs inhibit growth of MYC-driven tumors in vivo

Summary

Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.

Cited by (0)

13

Co-first author